Sethi Jaswinder K, Vidal-Puig Antonio
Department of Clinical Biochemistry, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QR, UK.
Trends Mol Med. 2005 Aug;11(8):344-7. doi: 10.1016/j.molmed.2005.06.010.
Human obesity-related diabetes and the accompanying metabolic disorders have been specifically linked to increased visceral adipose tissue mass. Understanding the differences in biology of the two human fat depots (visceral and subcutaneous) might hold the key to therapeutic strategies aimed at reducing obesity-induced insulin resistance and alleviating symptoms of the metabolic syndrome. Visfatin (pre-B-cell colony-enhancing factor, PBEF) is a novel adipokine that appears to be preferentially produced by visceral adipose tissue and has insulin-mimetic actions. Could this molecule hold the key to future treatments for type 1 and 2 diabetes? This article discusses the pros and cons of visfatin action and how it might affect future therapeutic strategies.
人类肥胖相关的糖尿病及伴随的代谢紊乱已被明确与内脏脂肪组织量增加相关联。了解两种人体脂肪储存部位（内脏和皮下）生物学特性的差异，可能是旨在降低肥胖诱导的胰岛素抵抗并缓解代谢综合征症状的治疗策略的关键所在。内脂素（前B细胞集落增强因子，PBEF）是一种新型脂肪因子，似乎优先由内脏脂肪组织产生且具有胰岛素模拟作用。这个分子会是1型和2型糖尿病未来治疗的关键吗？本文讨论了内脂素作用的利弊以及它可能如何影响未来的治疗策略。
